

Special Issue on Nanotherapeutics: Newer Remedies in Liver Disorder

CALL FOR PAPERS

Liver is the functional organ responsible for the metabolism and excretion of xenobiotics that enter human body through diverse passages. Disorders of liver are one of the most serious health hazards with an escalating growth rate affecting population across the globe. Viral hepatitis, cirrhosis, and hepatocellular carcinoma are frequently encountered liver diseases with high morbidity and mortality worldwide. In fact, they are rated among the top ten mortality causes in developed nations like US. But the complexity increases further when prolonged treatment with antitubercular, antiretroviral, or anticancer chemotherapy also contribute towards liver disorders. Conventional therapeutics often fails in liver treatment due to their rapid clearance by first pass effect. Adding to that, few therapeutic choices exist for liver treatment with significant hepatic specificity.

With the increasing influence of nanotechnology in modern medicine, diverse nanoscale therapeutic devices like polymer-based, lipid-based, metal complex, and bionanocapsules have become promising options in liver treatment. These newer therapeutics, because of their tailor-made size and surface features, exhibit immense selectivity towards liver thereby dampening chances of nonspecific organ toxicities. Besides, nanotherapeutics are also often explored to improve upon biopharmaceutical limitations of bioactivities like poor solubility or short biological half-life. Popularity of this newer therapeutics in hepatic treatment is linked to their high degree of selectivity and speedy cellular localization.

The purpose of this special issue is to publish high-quality research papers as well as extensive review articles related to newer nanotherapeutics development for mitigation of liver disorders. Original, high quality research contributions that are not yet published or that are not currently under review by other journals or peer-reviewed conferences are invited for this issue.

Potential topics include but are not limited to the following:

- ▶ Nanotherapeutics in liver fibrosis
- ▶ Nanotherapeutics in drug induced liver injury
- ▶ Targeted Nanotherapeutics in liver diseases
- ▶ Theranostic Nanotherapeutics in liver diseases
- ▶ Nanotherapeutics in liver carcinoma
- ▶ Natural product based nanotherapeutics in liver diseases

Authors can submit their manuscripts through the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/pharmaceutics/nnrld/>.

Lead Guest Editor

Suvadra Das, University of Calcutta,
Kolkata, India
suvadra.tech@gmail.com

Guest Editors

Partha Roy, Adamas University,
Kolkata, India
partharoy2502@gmail.com

Randolph D. Glickman, University of
Texas Health Science, Texas, USA
glickman@uthscsa.edu

Deepak Hegde, GSK, Shanghai, China
ddhegde2003@yahoo.co.in

Rudolf Urbanics,
Semmelweis University, Budapest,
Hungary
urbanicsr@gmail.com

Manuscript Due

Friday, 6 January 2017

First Round of Reviews

Friday, 31 March 2017

Publication Date

Friday, 26 May 2017